Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 28-02 / BIG 1-01 (HERA) 

HERA: A randomized, three-arm, multicenter comparison of 1 year and 2 years of herceptin vs. no herceptin in women with HER2 positive primary breast cancer who have completed adjuvant chemotherapy

DESIGN

Design Trial 28-02

Results & Publications


Presentations


Publications

Study Chairs
IBCSG: Dr. Olivia Pagani - Mendrisio, Switzerland
BIG: Dr. Martine J. Piccart - Brussels, Belgium

Lead Trial Coordinator
Holly Shaw


IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg28_hera@fstrf.org


Date of Activation
June 1998

Date of Closure
June 20, 2005 

Targeted Accrual
2730 patients

Final Accrual
5102 patients


Results Publications Results & Publications


News

09.09.2018:
9.9.2018 - RACE FOR LIFE, Bundesplatz Bern

23.03.2018:
The next IBCSG Annual Meeting will take place in Barcelona, Spain on March 23 and 24, 2018

04.10.2017:
IBCSG Slide Deck ESMO 2017 available now

All News

 
  Print